Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology
Estroprogestins (EPs) are combinations of estrogen and progestin with several actions on women’s health. The different pharmacological composition of EPs is responsible for different clinical effects. One of the most used low-dose EP associations is ethinylestradiol 20 mcg plus levonorgestrel 100 mc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/102184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548044505088000 |
|---|---|
| author | Stefano Lello Andrea Cavani |
| author_facet | Stefano Lello Andrea Cavani |
| author_sort | Stefano Lello |
| collection | DOAJ |
| description | Estroprogestins (EPs) are combinations of estrogen and progestin with several actions on women’s health. The different pharmacological composition of EPs is responsible for different clinical effects. One of the most used low-dose EP associations is ethinylestradiol 20 mcg plus levonorgestrel 100 mcg in monophasic regimen (EE20/LNG100). This review summarizes clinical pharmacology, cycle control, and effects on lipid and glucose metabolism, coagulation, body weight/body composition, acne, and sexuality of EE20/LNG100. Overall, EE20/LNG100 combination is safe and well tolerated, and in several studies the incidence of adverse events in the treated group was comparable to that of the placebo group. Cycle control was effective and body weight/body composition did not vary among treated and untreated groups in most studies. The EE20/LNG100 combination shows mild or no effect on lipid and glucose metabolism. Lastly, EE20/LNG100 is associated with a low risk of venous thromboembolism (VTE). In conclusion, in the process of decision making for the individualization of EPs choice, EE20/LNG100 should be considered for its favorable clinical profile. |
| format | Article |
| id | doaj-art-3689167ec0a04856bfff70c45e83c982 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-3689167ec0a04856bfff70c45e83c9822025-02-03T06:42:16ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/102184102184Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical PharmacologyStefano Lello0Andrea Cavani1Gynecological Endocrinology, Pathophysiology of Menopause and Osteoporosis, IDI-IRCCS, Via Monti di Creta 104, 00167 Rome, ItalyLaboratory of Experimental Immunology, IDI-IRCCS, 00167 Rome, ItalyEstroprogestins (EPs) are combinations of estrogen and progestin with several actions on women’s health. The different pharmacological composition of EPs is responsible for different clinical effects. One of the most used low-dose EP associations is ethinylestradiol 20 mcg plus levonorgestrel 100 mcg in monophasic regimen (EE20/LNG100). This review summarizes clinical pharmacology, cycle control, and effects on lipid and glucose metabolism, coagulation, body weight/body composition, acne, and sexuality of EE20/LNG100. Overall, EE20/LNG100 combination is safe and well tolerated, and in several studies the incidence of adverse events in the treated group was comparable to that of the placebo group. Cycle control was effective and body weight/body composition did not vary among treated and untreated groups in most studies. The EE20/LNG100 combination shows mild or no effect on lipid and glucose metabolism. Lastly, EE20/LNG100 is associated with a low risk of venous thromboembolism (VTE). In conclusion, in the process of decision making for the individualization of EPs choice, EE20/LNG100 should be considered for its favorable clinical profile.http://dx.doi.org/10.1155/2014/102184 |
| spellingShingle | Stefano Lello Andrea Cavani Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology International Journal of Endocrinology |
| title | Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology |
| title_full | Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology |
| title_fullStr | Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology |
| title_full_unstemmed | Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology |
| title_short | Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology |
| title_sort | ethynilestradiol 20 mcg plus levonorgestrel 100 mcg clinical pharmacology |
| url | http://dx.doi.org/10.1155/2014/102184 |
| work_keys_str_mv | AT stefanolello ethynilestradiol20mcgpluslevonorgestrel100mcgclinicalpharmacology AT andreacavani ethynilestradiol20mcgpluslevonorgestrel100mcgclinicalpharmacology |